The diagnosis of cutaneous T-cell lymphoma (CTCL) requires accurate histopathology, including immunocytochemistry, as well as careful clinical appraisal and analysis for T-cell clonality. This paper reviews the key histologic features of mycosis fungoides (MF) and its variants, and of lymphomatoid papulosis (LyP). Mycosis fungoides is an epidermotropic CTCL that evolves through distinct disease...

s European Veterinary Conference Voorjaarsdagen 2008 | 91 Dermatology Cellular phenotype The classic neoplastic cells in canine CETL are CD3+ (a common marker of all T-lymphocytes) and in 80% of the cases CD4-/CD8+ cytotoxic T cells. In 20% of the cases, CD4-/CD8lymphocytes (natural killer cells) are found. In man, 90% of CETL cases are due to clonal expansion of T-helper lymphocytes (CD4+/CD8-...

Cutaneous T-cell lymphoma (CTCL) is a malignancy of a distinctive subset of T-helper cells designated "cutaneous T cells" because of their central role in the normal functioning of the skin immune system. Guided by selective adhesion molecules, activated/memory T cells of the skin immune system normally circulate among the skin, lymph nodes, and peripheral blood. Thus, a better understanding of...

1. Medina-Franco H, Urist MM, Fiveash J, et al. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 2001;8:204-8. 2. Bichakjian CK, Lowe L, Lao CD, et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 2007;110:1-12. 3. Baccarani A, Pompei B, Pedone A, et al. Merkel cell carcinoma of t...

Abstract Introduction: Extra-nodal exposition of T-cell non-hodgkin lymphoma (NHL) is extremely rare, and is frequently observed in patients with immune system dysfunction. Peripheral T-cell lymphoma does not express CD56 is rare. Malignant lymphoma of the uvula is exceedingly unusual. The current study reported a case of peripheral T-cell lymphoma of the uvula in an immunecompetent patient. ...

Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma/leukemia. CCR4 is an important therapeutic target molecule because mogamulizumab, an anti-CCR4 antibody, has shown promising efficacy against various T-cell lymphomas. In this study, we examined the in vitro synergistic effe...

Cutaneous T-cell lymphoma (CTCL) is the most common primary lymphoma of the skin. As with most cancers, survival depends on the stage of disease. Infection is a common complication of CTCL, contributing significant morbidity and mortality. We report a patient with severe, generalized mycosis fungoides (MF) complicated by recurrent skin infections,and we review the infectious complications of pa...

A variety of novel therapeutic modalities have recently become available for patients with cutaneous T cell lymphoma (CTCL). In particular, with recent FDA approvals of the three new agents vorinostat (Zolinza), romidepsin (Istodax), and pralatrexate (Folotyn) CTCL treatment has been transformed. Here, we offer a brief overview of these agents and discuss their place in the spectrum of current ...

Primary cutaneous lymphomas can be difficult to be distinguished from reactive mimics, even when integrating histologic, immunophenotypic, and clinical findings. Molecular studies, especially PCR-based antigen receptor gene rearrangement (ARGR) analysis, are frequently useful ancillary studies in the evaluation of cutaneous lymphoproliferations. The biologic basis of ARGR studies is discussed, ...